ES2654931T3 - Derivados de pirazolo[1,5-a]piridina y procedimientos de uso de los mismos - Google Patents

Derivados de pirazolo[1,5-a]piridina y procedimientos de uso de los mismos Download PDF

Info

Publication number
ES2654931T3
ES2654931T3 ES14824711.7T ES14824711T ES2654931T3 ES 2654931 T3 ES2654931 T3 ES 2654931T3 ES 14824711 T ES14824711 T ES 14824711T ES 2654931 T3 ES2654931 T3 ES 2654931T3
Authority
ES
Spain
Prior art keywords
fluoro
phenyl
pyridin
pyrazolo
yloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14824711.7T
Other languages
English (en)
Spanish (es)
Inventor
Robert L. Hudkins
Allison L. Zulli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ignyta Inc
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Application granted granted Critical
Publication of ES2654931T3 publication Critical patent/ES2654931T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES14824711.7T 2013-12-26 2014-12-18 Derivados de pirazolo[1,5-a]piridina y procedimientos de uso de los mismos Active ES2654931T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920819P 2013-12-26 2013-12-26
US201361920819P 2013-12-26
PCT/US2014/071040 WO2015100117A1 (en) 2013-12-26 2014-12-18 Pyrazolo[1,5-a]pyridine derivatives and methods of their use

Publications (1)

Publication Number Publication Date
ES2654931T3 true ES2654931T3 (es) 2018-02-15

Family

ID=52293273

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14824711.7T Active ES2654931T3 (es) 2013-12-26 2014-12-18 Derivados de pirazolo[1,5-a]piridina y procedimientos de uso de los mismos

Country Status (22)

Country Link
US (2) US9914731B2 (enExample)
EP (2) EP3309160A1 (enExample)
JP (1) JP2017500362A (enExample)
KR (1) KR20160110390A (enExample)
CN (1) CN106029661B (enExample)
AU (1) AU2014370186A1 (enExample)
BR (1) BR112016015057A2 (enExample)
CA (1) CA2934667A1 (enExample)
CL (1) CL2016001604A1 (enExample)
DK (1) DK3087070T3 (enExample)
EA (2) EA201890061A3 (enExample)
ES (1) ES2654931T3 (enExample)
HU (1) HUE037579T2 (enExample)
IL (1) IL246311A0 (enExample)
MX (1) MX2016008445A (enExample)
NO (1) NO3014707T3 (enExample)
PH (1) PH12016501232A1 (enExample)
PL (1) PL3087070T3 (enExample)
PT (1) PT3087070T (enExample)
SG (1) SG11201605207PA (enExample)
SI (1) SI3087070T1 (enExample)
WO (1) WO2015100117A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053067T2 (hu) * 2015-07-16 2021-06-28 Array Biopharma Inc Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
CN106467541B (zh) 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
CN106543145B (zh) * 2016-10-28 2019-07-19 山西医科大学 c-Met激酶抑剂3-(4-氟苯基)嘧啶酮-5-甲酸酰胺衍生物、制备方法与应用
AU2017395023B2 (en) * 2016-12-23 2022-04-07 Plexxikon Inc. Compounds and methods for CDK8 modulation and indications therefor
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
JP7377798B2 (ja) * 2017-11-24 2023-11-10 南京明徳新薬研発有限公司 c-MET/AXL阻害剤としてのウラシル系化合物
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
ES2985569T3 (es) * 2018-08-24 2024-11-06 Transthera Sciences Nanjing Inc Nuevo inhibidor de derivado de quinolina
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての縮合複素環式化合物
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110467616B (zh) * 2019-07-01 2021-12-21 江西科技师范大学 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
CN110330479A (zh) * 2019-07-19 2019-10-15 南京华威医药科技集团有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
AU2020342108B2 (en) 2019-09-06 2024-03-07 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021197276A1 (en) 2020-03-30 2021-10-07 Hutchison Medipharma Limited Amide compounds and uses thereof
EP4371978A4 (en) * 2021-07-13 2025-09-10 Nippon Soda Co PROCESS FOR PRODUCING A URACIL COMPOUND
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori
CN116655626B (zh) * 2023-05-24 2025-03-11 遵义医科大学 一种含咪唑并[l,2-a]吡啶骨架的环丙二酰胺化合物及其制备方法和用途
AU2024319770A1 (en) * 2023-08-07 2026-02-19 Cogent Biosciences, Inc. Compounds for fgfr inhibition
WO2025111224A1 (en) * 2023-11-21 2025-05-30 Fmc Corporation Linked bicyclic compounds for controlling and combating invertebrate pests

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
MX2008011220A (es) * 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
BRPI0720169A2 (pt) * 2006-12-12 2013-12-24 Takeda Pharmaceutical Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto
EP1972628A1 (en) 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizines and aza-analog derivatives thereof as CNS active compounds
EP2320907A4 (en) 2008-08-05 2012-09-05 Merck Sharp & Dohme THERAPEUTIC COMPOUNDS
RS61281B1 (sr) * 2009-12-31 2021-02-26 Hutchison Medipharma Ltd Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora
AU2012220572A1 (en) * 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
AU2012294917A1 (en) * 2011-08-10 2014-03-20 Merck Patent Gmbh Pyrido-pyrimidine derivatives
WO2013043715A1 (en) * 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
UY34451A (es) * 2011-11-14 2013-05-31 Cephalon Inc Derivados de uracilo como inhibidores de la quinasa axl y c-met
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use

Also Published As

Publication number Publication date
CN106029661A (zh) 2016-10-12
DK3087070T3 (en) 2017-12-04
HUE037579T2 (hu) 2018-09-28
SI3087070T1 (en) 2018-01-31
EA029757B1 (ru) 2018-05-31
NO3014707T3 (enExample) 2018-01-06
CL2016001604A1 (es) 2017-05-26
CN106029661B (zh) 2017-11-03
WO2015100117A1 (en) 2015-07-02
EA201691164A1 (ru) 2016-12-30
KR20160110390A (ko) 2016-09-21
SG11201605207PA (en) 2016-07-28
MX2016008445A (es) 2016-10-28
AU2014370186A1 (en) 2016-07-14
EA201890061A2 (ru) 2018-05-31
AU2014370186A2 (en) 2016-07-21
BR112016015057A2 (pt) 2017-08-08
CA2934667A1 (en) 2015-07-02
EP3309160A1 (en) 2018-04-18
EP3087070B1 (en) 2017-11-08
US20160318929A1 (en) 2016-11-03
PT3087070T (pt) 2018-01-30
US9914731B2 (en) 2018-03-13
IL246311A0 (en) 2016-08-02
PL3087070T3 (pl) 2018-03-30
US20180148447A1 (en) 2018-05-31
EA201890061A3 (ru) 2018-09-28
PH12016501232A1 (en) 2016-08-15
JP2017500362A (ja) 2017-01-05
EP3087070A1 (en) 2016-11-02

Similar Documents

Publication Publication Date Title
EP3087070B1 (en) Pyrazolo[1,5-a]pyridine derivatives and methods of their use
KR102374844B1 (ko) 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도
ES2873515T3 (es) Derivado de quinolona, sal o estereoisómero del mismo farmacéuticamente aceptable, como inhibidor de AXL
ES2615238T3 (es) Derivados de tetrahidroquinolinas como inhibidores de bromodominio
ES2424651T3 (es) Nuevo derivado de piridina y derivado de pirimidina (3)
RU2582610C2 (ru) Производные хинолина и содержащие их ингибиторы melk
ES2368876T3 (es) Derivados de 2-heteroarilaminopirimidina como inhibidores de cinasa.
ES2472323T3 (es) Compuestos de piridina
KR102038462B1 (ko) Pi3k의 활성 또는 기능의 억제제의 용도
ES2852351T3 (es) Pirrolamidas como inhibidores de la integrina alfa V
ES2375735T3 (es) Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas.
CN117279910A (zh) Bcl6蛋白水解的调节剂和其相关使用方法
CN113773308A (zh) Rho激酶抑制剂
ES2842230T3 (es) Compuestos terapéuticos como inhibidores del receptor de orexina-1
KR102388312B1 (ko) 아미노피리미딘 화합물, 이의 제조방법 및 용도
HK1217482A1 (en) Enzyme modulators and therapies
MX2014008647A (es) Compuesto de pirazin-carboxamida.
AU2003261807A1 (en) Azaarene derivatives
CN104507933A (zh) 氨基喹唑啉和吡啶并嘧啶衍生物
KR20130036201A (ko) 헤타릴아미노나프티리딘
Liu et al. Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase
CN111918863B (zh) 杂环化合物
CN112074511A (zh) 取代的苯并二唑及其在治疗中的用途
HK40064586A (en) Rho kinase inhibitors
HK40062730A (en) Rho kinase inhibitors